NASDAQ: ADMA · Biotechnology

ADMA Biologics (ADMA) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values ADMA Biologics (ADMA) at $15.96 a share. The stock last closed at $13.47, which puts the model's fair value 18.5% above the price. On the model's bands that reads as Undervalued.

Revalued . Price is the close of 16 Nov 2026. ADMA Biologics, Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$15.96midpoint of 2,000 simulations
Last close$13.47NASDAQ: ADMA
Gap to fair value+18.5%fair value against price
Model verdictUndervaluedevidence grade: Medium

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $14.86 to $15.96 (+7.4%). The multiple the model anchors on moved, lifting the fair value: most of the move.

What the model makes of itThe price of $13.47 is 18.5% below it: Undervalued, on a medium evidence grade.

What's nextNext report on 24 Feb 2027. Options prices imply a move of about 15% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give ADMA?

The calibrated range for ADMA over 63 trading days is $11.37 to $16.10. It sits around the last close, and its width comes from the volatility that ADMA's own options imply (51% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $9.88 to $24.58. In 61% of the simulations the fair value came out above the price the model ran on.

$5.62$47.24
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $15.96. Dashed line: the last close, $13.47.

Faircurve Insights · 14 Nov 2026

ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures and commercialises advanced biologic therapies derived from blood plasma.

Faircurve's model gives a fair value of $15.96 a share for ADMA Biologics, the midpoint of 2,000 simulations, on the run of 14 Nov 2026. The previous run, on 7 Nov 2026, gave $14.86, so the fair value moved +7.4%. The reason, in the model's own words: the multiple it anchors on moved, lifting the fair value, most of the move. The calibrated range over 63 trading days is $11.63 to $16.23, built from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is Medium, based on input completeness, the number and agreement of comparable companies, and the width of outcomes. It does not say whether the fair value is right.

ADMA's overall quality score is 68 out of 100 against comparable companies. Profitability scores 100: ROIC 35.1%, peer median -54.4%. Capital discipline scores 100: net buybacks 6.2% of market value, peer median 0.0%. Stability scores 0: EBITDA margin downside volatility 29.7 pts over five years. Comparables are Vericel Corporation (VCEL), Acadia Pharmaceuticals Inc. (ACAD) and Fortrea Holdings Inc. (FTRE).

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does ADMA report earnings, and how has the stock reacted?

ADMA Biologics's next earnings report is scheduled for 24 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 12.0% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. ADMA's 30 day implied volatility works out to about 14.9% over one month.

Around its last 3 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ADMA's last 8 reports, ignoring direction, was 12.3%.

0%5%10%15%20%17.1%17.4%6 May '26no quote12.9%5 Aug '2612.9%18.9%4 Nov '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

Earlier reports are left out: the options record before 28 Mar 2026 is not comparable.

What the options market has priced for a month's move in ADMA

5%10%15%20%25%30%35%4 Nov '26 report5 Aug '26 report6 May '26 report15% at 16 Nov '262 Apr '2616 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 33% on 2 Apr 2026, reached 33% on 2 Apr 2026 and reads 15% on 16 Nov 2026. The marks are report dates.

How does ADMA score on business quality?

ADMA Biologics's overall quality score is 68 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.10035.1%ROIC-54.4%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).400.73xFCF / net income
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.6119.6%Revenue growth, trailing
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.1006.2%Net buybacks / market value0.0%
Balance sheetNet debt to EBITDA and interest coverage.760.31xNet debt / EBITDA
StabilityDownside volatility of the EBITDA margin over the last five years.029.7 ptsEBITDA margin downside volatility, 5y

How does ADMA compare with similar companies?

The companies in biotechnology closest to ADMA Biologics in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
VCEL Vericel Corporation$57.48$65.96+14.8%Fairly valued
ACAD Acadia Pharmaceuticals Inc.$18.67$23.24+24.5%Undervalued
XNCR Xencor, Inc.$35.40$35.72+0.9%Low evidence grade
RCUS Arcus Biosciences, Inc.$16.86$16.32-3.2%Low evidence grade
HRMY Harmony Biosciences Holdings, Inc.$32.96$33.93+2.9%Low evidence grade
FTRE Fortrea Holdings Inc.$19.79$24.79+25.3%Undervalued
PTCT PTC Therapeutics, Inc.$60.97$74.62+22.4%Low evidence grade
SRPT Sarepta Therapeutics, Inc.$15.13$19.51+28.9%Low evidence grade

What the comparable companies' multiples alone would give for ADMA, the peer-implied price, is $169.78 a share on this run. The fair value weighs that against the company's own multiple.

All biotechnology stocks ranked by gap to fair value

ADMA Biologics at a glance

ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma.

Market value
$3.0B
Sector
Healthcare
Industry
Biotechnology
Revenue expected, next twelve months
$603M
Consensus revenue growth, next fiscal year
+4.8%
Analysts with estimates
3
Beta to the US market
-0.26
First valued by Faircurve
11 Jul 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ADMA was among them.

How the fair value is worked out: the model prices ADMA Biologics on the value of the whole business, debt included, against the revenue analysts expect next year (forward EV/Sales), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for ADMA was $14.86. As of 14 Nov 2026 it is $15.96, a change of +7.4%. The multiple the model anchors on moved, lifting the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about ADMA Biologics's valuation

Is ADMA Biologics stock undervalued or overvalued?

On Faircurve's model, ADMA reads as Undervalued as of 14 Nov 2026. The model's fair value is $15.96 a share against a last close of $13.47, a gap of +18.5%.

What is ADMA's fair value?

$15.96 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $9.88 to $24.58.

What price range does the model give ADMA?

$11.37 to $16.10 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does ADMA Biologics report earnings next?

The next report is scheduled for 24 Feb 2027. Companies can move their dates.

How much has ADMA moved on past earnings reports?

Across its last 8 reports the median two session move was 12.3%, ignoring direction. The largest was +18.9% around the report of 4 Nov 2026.

How confident is the model in this valuation?

The model's evidence grade for ADMA is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on ADMA

The model holds no idea open on ADMA today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ADMA with their outcomes. A free account is enough.

Keep reading